Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Auteur de référence en rhumatologie
35 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
65.4 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
GCS LNA SANTE PUI SERRIS SIEGE
INSTITUT MEDICAL DE SERRIS CRS DU RHIN, 77700 SERRIS
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Brain : a journal of neurology · 2024
AbstractEstimates of the spectrum and frequency of pathogenic variants in Parkinson’s disease (PD) in different populations are currently limited and biased. Furthermore, although therapeutic modification of several genetic targets has reached the clinical trial stage, a major obstacle in conducting these trials is that PD patients are largely unaware of their genetic status and, therefore, cannot be recruited. Expanding the number of investigated PD-related genes and including genes related to disorders with overlapping clinical features in large, well-phenotyped PD patient groups is a prerequisite for capturing the full variant spectrum underlying PD and for stratifying and prioritizing patients for gene-targeted clinical trials. The Rostock Parkinson’s disease (ROPAD) study is an observational clinical study aiming to determine the frequency and spectrum of genetic variants contributing to PD in a large international cohort.We investigated variants in 50 genes with either an established relevance for PD or possible phenotypic overlap in a group of 12 580 PD patients from 16 countries [62.3% male; 92.0% White; 27.0% positive family history (FH+), median age at onset (AAO) 59 years] using a next-generation sequencing panel.Altogether, in 1864 (14.8%) ROPAD participants (58.1% male; 91.0% White, 35.5% FH+, median AAO 55 years), a PD-relevant genetic test (PDGT) was positive based on GBA1 risk variants (10.4%) or pathogenic/likely pathogenic variants in LRRK2 (2.9%), PRKN (0.9%), SNCA (0.2%) or PINK1 (0.1%) or a combination of two genetic findings in two genes (∼0.2%). Of note, the adjusted positive PDGT fraction, i.e. the fraction of positive PDGTs per country weighted by the fraction of the population of the world that they represent, was 14.5%. Positive PDGTs were identified in 19.9% of patients with an AAO ≤ 50 years, in 19.5% of patients with FH+ and in 26.9% with an AAO ≤ 50 years and FH+. In comparison to the idiopathic PD group (6846 patients with benign variants), the positive PDGT group had a significantly lower AAO (4 years, P = 9 × 10−34). The probability of a positive PDGT decreased by 3% with every additional AAO year (P = 1 × 10−35). Female patients were 22% more likely to have a positive PDGT (P = 3 × 10−4), and for individuals with FH+ this likelihood was 55% higher (P = 1 × 10−14). About 0.8% of the ROPAD participants had positive genetic testing findings in parkinsonism-, dystonia/dyskinesia- or dementia-related genes.In the emerging era of gene-targeted PD clinical trials, our finding that ∼15% of patients harbour potentially actionable genetic variants offers an important prospect to affected individuals and their families and underlines the need for genetic testing in PD patients. Thus, the insights from the ROPAD study allow for data-driven, differential genetic counselling across the spectrum of different AAOs and family histories and promote a possible policy change in the application of genetic testing as a routine part of patient evaluation and care in PD.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Cancer treatment and research communications · 2026 · Journal Article
Chauhan B, Kumar D, Ahmad A, Haque Z, et al.
Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace · 2026 · Journal Article
Akhil A, Joseph JR, Puttegowda VD, V M, et al.
Biomedical physics & engineering express · 2025 · Journal Article
D K, D P, P V, G A, et al.
Cureus · 2025 · Journal Article
Chintham S, S M, Periasamy P, Gopalakrishnan S
PloS one · 2025 · Journal Article
S DSN, Sundararajan V
Journal of orthopaedic case reports · 2025 · Journal Article
Annapareddy A, Bose VC, Katariya AA, Mulpur P, et al.
Indian journal of community medicine : official publication of Indian Association of Preventive & Social Medicine · 2024 · Journal Article
Babu H, Sriraman S, Karthikbabu S, Sophia P, et al.
Physics in medicine and biology · 2023 · Journal Article
Sebastián SM, Alejandro C, Ignacio E, Sophia G, et al.
PLoS neglected tropical diseases · 2023 · Journal Article
Guttapadu R, Prakash N, M A, Chatterjee R, et al.
Discover oncology · 2023 · Journal Article
Krishna A, Hasib AG, Fernandes D, Athiyamaan MS, et al.
Health economics review · 2025 · Journal Article
Shobha V, Singhai S, Haridas V, V S, et al.
Cureus · 2024 · Case Reports
Agrawal AC, Sarkar S, Sakale H, Rojasara J, et al.
MethodsX · 2024 · Journal Article
Shetty S, Gudi N, S EAR, Maiya GA, et al.
Cureus · 2024 · Journal Article
S D, R K
International journal of surgery case reports · 2026 · Case Reports
Musse AI, Sleyum SA, Goretty L, Sophia N, et al.
Cureus · 2025 · Case Reports
Ghosh S, Vittobarao PG, S S, L A, et al.
Cureus · 2024 · Case Reports
Agrawal AC, Sarkar S, Sakale H, Rojasara J, et al.
Cureus · 2024 · Case Reports
S V, Murugesan H, Ramanathan K, Selvaraj C
Cureus · 2025 · Journal Article
S Y, Radhakrishnan P, Krishnamurthy D, Cherukkumalli N, et al.
Cureus · 2023 · Journal Article
S S, R S
Bioinformation · 2022 · Journal Article
R V, G K, G S, S M
Frontiers in immunology · 2025 · Journal Article
E K KP, P R S, S S, Banerjee M
Brain : a journal of neurology · 2024 · Journal Article
Westenberger A, Skrahina V, Usnich T, Beetz C, et al.
Frontiers in immunology · 2026 · Journal Article
Khatri R, Jose A, Rajadhyaksha A, Mehta K, et al.
Lupus · 2023 · Journal Article
Patil A, Shobha V, Shenoy P, S C, et al.
Health science reports · 2025 · Journal Article
Ekaterina K, Saba I, Sophia A, Ivane A, et al.
Cureus · 2024 · Case Reports
Jayakumar A, S H, Philip T, Jomey MR
Mediterranean journal of rheumatology · 2025 · Journal Article
S C, Shenoy P, Kumar U, Pandya S, et al.
Journal of medicinal food · 2025 · Journal Article
Jayaram M, Kim J, Baek KS, Jung H, et al.
Cureus · 2024 · Case Reports
Sharma PK, S S, Christina EP, Gunasekaran D
The Journal of surgical research · 2026 · Journal Article
Erin W, Sophia S, Allison C, Ben K, et al.
Annals of rehabilitation medicine · 2025 · Journal Article
Agarwal V, S J, Sharma A
MethodsX · 2024 · Journal Article
Shetty S, Gudi N, S EAR, Maiya GA, et al.
Cureus · 2023 · Journal Article
J S, S L, Nair MV, R KT, et al.
Clinical and experimental medicine · 2023 · Observational Study
S B, Naidu G, Sharma A, Minz RW, et al.
Annals of rehabilitation medicine · 2024 · Journal Article
Agarwal V, S J, Sharma A
Frontiers in immunology · 2023 · Journal Article
Faiyazuddin M, Sophia A, Ashique S, Gholap AD, et al.